OpenMed-NER-OncologyDetect-MultiMed-335M

模型介绍

This model is a **state-of-the-art** fine-tuned transformer engineered to deliver **enterprise-grade accuracy** for cancer genetics - cancer-related genetic entities. This specialized model excels at identifying and extracting biomedical entities from clinical texts, research papers, and healthcare documents, enabling applications such as **drug interaction detection**, **medication extraction from patient records**, **adverse event monitoring**, **literature mining for drug discovery**, and **biomedical knowledge graph construction** with **production-ready reliability** for clinical and research applications. The BioNLP 2013 CG (Cancer Genetics) corpus is a specialized dataset focusing on cancer genetics entities and gene regulation in oncology research. This corpus contains annotations for genes, proteins, and molecular processes specifically related to cancer biology and tumor genetics. Developed for the BioNLP Shared Task 2013, it supports the development of text mining systems for cancer research, oncological studies, and precision medicine applications. The dataset is particularly valuable for identifying cancer-related biomarkers, tumor suppressor genes, oncogenes, and therapeutic targets mentioned in cancer research literature. It serves as a benchmark for evaluating NER systems used in cancer genomics, personalized medicine, and oncology informatics. *Figure: OpenMed (Open-Source) vs. Latest SOTA (Closed-Source) performance comparison across biomedical NER datasets.*

主要特点

特点摘要待依据来源补齐，不凭模型名称推断能力。

局限与注意事项

暂无足够来源支持具体缺点结论。请重点验证实际任务表现、时延、数据政策、许可与版本生命周期。

来源报价与费用分析

同一模型在不同渠道、地区和配置下可能采用不同价格。下表独立保留各渠道报价，不将渠道价格视为厂商官方统一价格。

公开评测与运行配置

暂无已采集的可核验公开评分。模型未上榜不代表能力较低。

常见问题

资料来源与可追溯记录

许可证：apache-2.0。模型介绍与第三方评测均以原来源的具体版本和方法为准。